BlossomHill Therapeutics, Inc. (BLSM)
$26.74+$0.57 (+2.17%) Latest session
Bihua Chen - DirectorBlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 7 | 1,573,900 | $25.18M |
| Grant or award | 8 | 1,025,708 | |
| Other acquisition / disposition | 28 | 23,518,190 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
11 Form 4 filings on record, the earliest from Aug 10, 2026, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Carl L. Gordon - Director | Other | Common Stock | 1,039,996 | - | - | |
| Carl L. Gordon - Director | Other | Common Stock | 1,049,283 | - | - | |
| Carl L. Gordon - Director | Open-market purchase | Common Stock | 625,000 | $16.00 | $10.00M | |
| Carl L. Gordon - Director | Other | Series A Preferred Stock | 1,039,996 | $0.00 | - | |
| Carl L. Gordon - Director | Other | Series B Preferred Stock | 1,049,283 | $0.00 | - | |
| ORBIMED ADVISORS LLC - Director | Other | Common Stock | 1,039,996 | - | - | |
| ORBIMED ADVISORS LLC - Director | Other | Common Stock | 1,049,283 | - | - | |
| ORBIMED ADVISORS LLC - Director | Open-market purchase | Common Stock | 625,000 | $16.00 | $10.00M | |
| ORBIMED ADVISORS LLC - Director | Other | Series A Preferred Stock | 1,039,996 | $0.00 | - | |
| ORBIMED ADVISORS LLC - Director | Other | Series B Preferred Stock | 1,049,283 | $0.00 | - | |
| John P. Schmid - Director | Open-market purchase | Common Stock | 6,000 | $16.00 | $96K | |
| Carl L. Gordon - Director | Grant or award | Director Stock Option (Right to Buy) | 23,904 | $0.00 | - | |
| Bihua Chen - Director | Other | Common Stock | 1,599,993 | - | - | |
| Bihua Chen - Director | Other | Common Stock | 1,701,541 | - | - | |
| Bihua Chen - Director | Open-market purchase | Common Stock | 312,500 | $16.00 | $5.00M | |
| Bihua Chen - Director | Grant or award | Director Stock Option (Right to Buy) | 23,904 | $0.00 | - | |
| Bihua Chen - Director | Other | Series A Preferred Stock | 1,599,993 | - | - | |
| Bihua Chen - Director | Other | Series B Preferred Stock | 1,701,541 | - | - | |
| Sundeep Agrawal - Director | Other | Common Stock | 578,524 | - | - | |
| Sundeep Agrawal - Director | Grant or award | Director Stock Option (Right to Buy) | 23,904 | $0.00 | - | |
| Sundeep Agrawal - Director | Other | Series B Preferred Stock | 578,524 | - | - | |
| Jason A. Keyes - Officer | Open-market purchase | Common Stock | 700 | $16.00 | $11K | |
| Jason A. Keyes - Officer | Grant or award | Employee Stock Option (Right to Buy) | 56,746 | $0.00 | - | |
| Vincent Paul Liptak - Officer | Open-market purchase | Common Stock | 2,500 | $15.80 | $40K | |
| Vincent Paul Liptak - Officer | Open-market purchase | Common Stock | 2,200 | $16.00 | $35K | |
| Vincent Paul Liptak - Officer | Other | Common Stock | 22,687 | - | - | |
| Vincent Paul Liptak - Officer | Grant or award | Employee Stock Option (Right to Buy) | 46,561 | $0.00 | - | |
| Vincent Paul Liptak - Officer | Other | Series B Preferred Stock | 22,687 | - | - | |
| Geoffrey Raymond Oxnard - Officer | Grant or award | Employee Stock Option (Right to Buy) | 61,783 | $0.00 | - | |
| Yishan Li - Officer | Other | Common Stock | 1,600,682 | - | - | |
| Yishan Li - Officer | Other | Common Stock | 113,435 | - | - | |
| Yishan Li - Officer | Other | Common Stock | 124,779 | - | - | |
| Yishan Li - Officer | Grant or award | Employee Stock Option (Right to Buy) | 112,701 | $0.00 | - | |
| Yishan Li - Officer | Other | Series Angel Preferred Stock | 1,600,682 | - | - | |
| Yishan Li - Officer | Other | Series B Preferred Stock | 113,435 | - | - | |
| Yishan Li - Officer | Other | Series B Preferred Stock | 124,779 | - | - | |
| Jingrong Jean Cui - Officer | Other | Common Stock | 1,600,682 | - | - | |
| Jingrong Jean Cui - Officer | Other | Common Stock | 113,435 | - | - | |
| Jingrong Jean Cui - Officer | Other | Common Stock | 124,779 | - | - | |
| Jingrong Jean Cui - Officer | Grant or award | Employee Stock Option (Right to Buy) | 676,205 | $0.00 | - | |
| Jingrong Jean Cui - Officer | Other | Series Angel Preferred Stock | 1,600,682 | - | - | |
| Jingrong Jean Cui - Officer | Other | Series B Preferred Stock | 113,435 | - | - | |
| Jingrong Jean Cui - Officer | Other | Series B Preferred Stock | 124,779 | - | - |
BlossomHill Therapeutics, Inc. (BLSM) had 11 insider filings in the last 90 days, with the most recent on 2026-08-12. The full record for BLSM runs to 11 Form 4 filings, the earliest from 2026-08-10. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
7 insider purchases of BLSM were filed in the last 90 days, totaling $25.18M.
No insider sales of BLSM were filed in the last 90 days.
This page tracks BLSM Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add BLSM to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
